Loading
A phase 2 trial in pancreatic cancer, run by Erasme University Hospital, now recruiting.
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma is a phase 2, randomised interventional study registered as NCT05083247 by Erasme University Hospital, with a registry enrolment figure of 256 participants, started 2023-03-24 and due to reach its primary completion in 2027-12-31. Interventions recorded: mFOLFIRINOX or Gemcitabine nab-paclitaxel; Isotoxic High-Dose (iHD)-SBRT; Surgery. Conditions listed: Pancreatic Neoplasm; Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma. Primary outcome: Disease free survival; R0 Resection rate. Pancreatic eligibility wording from the registry: "* Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinated process or body or tail". Sites: Belgium. No results are recorded here; the registry entry is the source.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.